alexa Intermittent Claudication: The Importance of Non-Invasive Treatment in the Femoro-Popliteal Tract | OMICS International
ISSN: 2161-1076
Surgery: Current Research

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Intermittent Claudication: The Importance of Non-Invasive Treatment in the Femoro-Popliteal Tract

Luigi Venturini, Daniele Ferraro and Paolo Sapienza*

Department of Surgery, Pietro Valdoni Sapienza University, Rome, Italy

*Corresponding Author:
Paolo Sapienza, MD, PhD
Department of Surgery Pietro Valdoni Sapienza
University of Rome Policlinico Umberto I Viale delPoliclinico
Rome, Italy
Tel: +390649972780
Fax: +390649970794
E-mail: [email protected]

Received date:July 29, 2014; Accepted date: October 29, 2014; Published date: October 29,2014

Citation: Venturini L, Ferraro D, Sapienza P (2014) Intermittent Claudication: The Importance of Non-Invasive Treatment in the Femoro-Popliteal Tract. Surgery Curr Res 4:207. doi:10.4172/2161-1076.1000207

Copyright: 2014 Venturini L, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Surgery: Current Research


Patients affected with Peripheral arterial disease (PAD) mostly refer to physicians when Intermittent claudication (IC) occurs. Calf symptom ranging from fatigue to aching while walking is the usual clinical presentation.

The prevalence of intermittent claudication is around 4.5% in general population aged between 55 to 74 years [1]. Even if this condition has a profound and negative impact on patients’ quality of life [2,3], because of a sense of limitation of mobility and the fear of the progression of the disease and limb loss, patient should be reassured on the relatively benign prognosis of the pathology in case of intermittent claudication. Leng et al. [4] reported a remission of symptoms in more than 60% of the patients examined after a period of 5 years. A progression of the disease in only 25%; deterioration is more likely to appear on the first year after diagnosis (7%-9%) compared with 2% to 3% per year thereafter [5] and can be related to poor adherence to treatments and exercise programs.

IC is more often the result of a single level stenosis or occlusion (aorto-iliac or femoro-popliteal tract). According to the Inter-society Consensus for the Management of Peripheral Arterial Disease (TASC II) the treatment for claudication, in case of femoro-popliteal involvement should focus on risk factor modification and a program of supervised exercise [5]. This approach has been validated for its efficacy and costeffectiveness by several studies [6-9]. This is not a “wait and see” approach to PAD; physicians should consider IC as the “wedge of an iceberg” of widespread atherosclerosis involving the whole cardiovascular system. At this point of the disease, the base of treatment should be pharmacological (i.e. lipid-lowering, antiplatelet, antihypertensive and blood sugar regulator drugs) associated with the correction of unhealthy habits (i.e. sedentary lifestyle, smoking habit, and obesity). An early revascularization may lead the patient to underestimate the importance of risk factor and lifestyle modification whereas exercise training under a supervised setting, increase the perception of the disease. The importance of lowering the cardiovascular risk is more evident if we consider that these patients have a significantly higher risk of mortality from cardiovascular causes when compared to the normal population (RR : 2.67, P ≤ 0,01) [4].

If the pharmacologic or risk factor correction fails, intervention has also been advocated at this stage of the disease. In particular, endovascular procedures are recommended in TASC A lesions [5]. Endovascular interventions are attractive to patients and physicians because of lower morbidity and mortality rates, but angioplasty and stinting remains a controversial issue in patients experiencing claudication, especially for the femoro-popliteal district. Endovascular procedures have clearly demonstrated their role in contemporary practice with low morbidity and mortality. Even though, while treating our patients, we should always keep in mind that any kind of revascularization may be the onset of a vicious cycle of repeated interventions10 and that even if morbidity rates are low, they still exist [10,11]. This should not be underestimated when we propose invasive treatments to claudicating patients, who are affected with a mild peripheral arterial disease. Furthermore, an early endovascular approach may alter the distal arterial segments, which can be used as the distal anastomotic site for a future surgical bypass in the case of an endovascular failure [12]. These patients will be exposed to increased risks of surgical and medical complications and enormous medical costs that we can easily prevent by offering the best medical treatment and adequate encouragement for starting a supervised training program that is surely more fatiguing but at least as effective as invasive procedures [7,8,13]. A recent cost-analysis study estimated savings of up to 33 million euros per year if a supervised exercise training first approach for intermittent claudication is followed in the Dutch healthcare system [14].

In conclusion, at present we are convinced for an ethical and economic perspective that patients affected with IC should be treated conservatively; surgery either endovascular or open can be postponed as soon as the patients will develop significant and disabling symptoms.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Article Usage

  • Total views: 11710
  • [From(publication date):
    November-2014 - Jun 24, 2018]
  • Breakdown by view type
  • HTML page views : 7951
  • PDF downloads : 3759

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7